Security key
45826J105
Intellia Therapeutics, Inc. - Common Stock (NTLA)
CUSIP: 45826J105
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 118,202,207
- Total 13F shares
- 99,520,897
- Share change
- -2,430,737
- Total reported value
- $933,579,792
- Put/Call ratio
- 60%
- Price per share
- $9.38
- Number of holders
- 277
- Value change
- -$6,825,658
- Number of buys
- 147
- Number of sells
- 138
Report period
Q2 2025
Institutions
277
Top holders
10
NTLA full security history
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Intellia Therapeutics, Inc. SEC filings
Intellia Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 45826J105
Recent filing periods:
Top shareholders of NTLA - Intellia Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
8.2%
from 13D/G
|
10,556,190
|
$75,054,514 | — | 31 Mar 2025 | |
| ARK Investment Management LLC |
13F
|
Company |
11%
|
13,011,015
|
$92,508,319 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
9.1%
|
10,752,031
|
$76,446,941 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.8%
|
4,510,261
|
$32,067,956 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
3.2%
|
3,801,695
|
$27,030,056 | — | 31 Mar 2025 | |
| Capital International Investors |
13F
|
Company |
3.2%
|
3,779,424
|
$26,871,705 | — | 31 Mar 2025 | |
| REGENERON PHARMACEUTICALS, INC. |
13F
|
Company |
3.1%
|
3,702,995
|
$26,328,294 | — | 31 Mar 2025 | |
| Sumitomo Mitsui Trust Group, Inc. |
13F
|
Company |
2.4%
|
2,825,361
|
$20,088,317 | — | 31 Mar 2025 | |
| Amova Asset Management Americas, Inc. |
13F
|
Company |
2.4%
|
2,825,361
|
$20,003,556 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.3%
|
2,757,568
|
$19,606,308 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
2,480,173
|
$17,637,822 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2%
|
2,413,183
|
$17,157,732 | — | 31 Mar 2025 | |
| Contrarius Group Holdings Ltd |
13F
|
Company |
1.7%
|
2,021,040
|
$14,369,594 | — | 31 Mar 2025 | |
| Casdin Capital, LLC |
13F
|
Company |
1.7%
|
2,000,000
|
$14,220,000 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.7%
|
1,992,905
|
$14,169,555 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.7%
|
1,982,317
|
$14,094,274 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.7%
|
1,968,166
|
$13,996,761 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
1.3%
|
1,590,302
|
$11,307,048 | — | 31 Mar 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
1,515,614
|
$10,776,016 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
1.3%
|
1,515,085
|
$10,772,254 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.95%
|
1,126,804
|
$8,011,577 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.8%
|
945,583
|
$6,723,094 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.78%
|
917,761
|
$6,525,281 | — | 31 Mar 2025 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.67%
|
789,662
|
$5,614,519 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.66%
|
780,224
|
$5,547,393 | — | 31 Mar 2025 | |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. |
13F
|
Company |
0.64%
|
752,676
|
$5,351,526 | — | 31 Mar 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.54%
|
644,116
|
$4,579,665 | — | 31 Mar 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.51%
|
604,696
|
$4,299,389 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.5%
|
586,489
|
$4,169,937 | — | 31 Mar 2025 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.48%
|
565,000
|
$4,017,150 | — | 31 Mar 2025 | |
| Discovery Value Fund |
13F
|
Company |
0.48%
|
561,561
|
$3,992,699 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.46%
|
543,625
|
$3,865,173 | — | 31 Mar 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.44%
|
521,706
|
$3,709,329 | — | 31 Mar 2025 | |
| Jump Financial, LLC |
13F
|
Company |
0.43%
|
503,809
|
$3,582,082 | — | 31 Mar 2025 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.4%
|
475,946
|
$3,383,976 | — | 31 Mar 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.4%
|
471,676
|
$3,353,617 | — | 31 Mar 2025 | |
| PDT Partners, LLC |
13F
|
Company |
0.39%
|
460,246
|
$3,272,349 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.36%
|
429,105
|
$3,050,937 | — | 31 Mar 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.32%
|
381,080
|
$2,709,479 | — | 31 Mar 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
0.31%
|
364,000
|
$2,588,040 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.3%
|
357,558
|
$2,542,240 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.29%
|
340,457
|
$2,420,649 | — | 31 Mar 2025 | |
| Vestmark Advisory Solutions, Inc. |
13F
|
Company |
0.26%
|
311,882
|
$2,217,481 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.25%
|
297,406
|
$2,114,556 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.24%
|
281,943
|
$2,004,611 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.23%
|
272,297
|
$1,936,031 | — | 31 Mar 2025 | |
| Verition Fund Management LLC |
13F
|
Company |
0.23%
|
271,434
|
$1,929,896 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.21%
|
251,562
|
$1,788,605 | — | 31 Mar 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.21%
|
249,235
|
$1,772,061 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.2%
|
240,096
|
$1,707,083 | — | 31 Mar 2025 |
Institutional Holders of Intellia Therapeutics, Inc. - Common Stock (NTLA) as of Q2 2025
As of 30 Jun 2025,
Intellia Therapeutics, Inc. - Common Stock (NTLA) was held by
277 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
99,520,897 shares.
The largest 10 holders included
ARK Investment Management LLC, VANGUARD GROUP INC, BlackRock, Inc., MORGAN STANLEY, STATE STREET CORP, REGENERON PHARMACEUTICALS, INC., BAKER BROS. ADVISORS LP, Sumitomo Mitsui Trust Group, Inc., Nikko Asset Management Americas, Inc., and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
280
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
289
Q2 2025 holders
277
Holder diff
-12
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.